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Background: The medium-term effects of Coronavirus disease (COVID-19) on organ health, exercise capacity,
cognition, quality of life and mental health are poorly understood.
Methods: Fifty-eight COVID-19 patients post-hospital discharge and 30 age, sex, body mass index comorbid-
ity-matched controls were enrolled for multiorgan (brain, lungs, heart, liver and kidneys) magnetic reso-
nance imaging (MRI), spirometry, six-minute walk test, cardiopulmonary exercise test (CPET), quality of life,
cognitive and mental health assessments.
Findings: At 23 months from disease-onset, 64% of patients experienced breathlessness and 55% reported
fatigue. On MRI, abnormalities were seen in lungs (60%), heart (26%), liver (10%) and kidneys (29%). Patients
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2 B. Raman et al. / EClinicalMedicine 31 (2021) 100683demonstrated impaired cognitive performance, specifically in the executive and visuospatial domains. Exer-
cise tolerance (maximal oxygen consumption and ventilatory efficiency on CPET) and six-minute walk dis-
tance were significantly reduced. The extent of extra-pulmonary MRI abnormalities and exercise intolerance
correlated with serum markers of inflammation and acute illness severity. Patients had a higher burden of
self-reported symptoms of depression and experienced significant impairment in all domains of quality of
life compared to controls (p<0.0001 to 0.044).
Interpretation: A significant proportion of patients discharged from hospital reported symptoms of breath-
lessness, fatigue, depression and had limited exercise capacity. Persistent lung and extra-pulmonary organ
MRI findings are common in patients and linked to inflammation and severity of acute illness.
Funding: NIHR Oxford and Oxford Health Biomedical Research Centres, British Heart Foundation Centre for
Research Excellence, UKRI, Wellcome Trust, British Heart Foundation.








The global impact of Coronavirus disease or COVID-19 has been
profound with hundreds of thousands of lives lost and millions
affected. [1] Despite the high mortality seen among hospitalised
patients, many have survived, with little known about the medium-
to-long term effects of COVID-19 after discharge. Although predomi-
nantly a respiratory illness, emerging data suggests that multiorgan
injury is common, particularly in those with moderate to severe
infections. [24]
Studies have shown that the brain, heart, gastrointestinal system
and the kidneys are particularly vulnerable to injury during the initial
phase of illness. [2-4] The invasive potential and affinity of severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) for multiple
cell lines suggests that virus-mediated toxicity may play a central
role in promoting multi-system damage. [5] An exaggerated and dys-
regulated immune response, endothelial damage, thromboinflamma-
tion and coagulopathy have also been implicated in causing injury to
these organs. [6]
While it is clear that the extent of infection, inflammatory
response and physiological reserve (influenced by obesity, age and
comorbidities) are important determinants of clinical outcomes dur-
ing the initial phase, reports of a chronic maladaptive inflammatory
syndrome are also emerging. In particular, inflammatory changes in
the lungs have been described in convalescing patients, months after
discharge from hospital. [7] Whether extra-pulmonary organs are
also susceptible to ongoing inflammation and injury is poorly under-
stood, as are its effects on exercise tolerance, cognition, mental health
and quality of life.
In a holistic study of survivors of moderate to severe COVID-19
infection discharged from hospital, at 2-3 months from disease onset,
we aimed to investigate the prevalence of persistent multiorgan
injury/inflammation and assess the effects of COVID-19 on physical,
psychological, cognitive health and well-being.2. Methods
2.1. Study population
Fifty-eight patients with moderate to severe laboratory-confirmed
(SARS-CoV-2 polymerase chain reaction positive) COVID-19, admitted
for treatment at the Oxford University Hospitals National Health Service
Foundation Trust between 14th March  25th May 2020, and 30 unin-
fected controls (SARS-CoV-2 immunoglobulin negative and asymptom-
atic) group-matched for age, sex, body mass index (BMI) and risk
factors (smoking, diabetes and hypertension) from the community (dur-
ing the same period) were prospectively enrolled in this observational
cohort study (appendix, Figure 1, p27). Enrolment did not rely on the
presence of multi-organ symptoms (neurological, cardiac, respiratory,
gastrointestinal) and hence our patients were an unselected cohort of
hospitalised individuals with moderate to severe COVID-19. Patientswere approached by their medical team either at the time of discharge
or after discharge and invited to participate in our study. Controls were
identified from other ethically approved studies and by word of mouth
as stated in our research ethics protocol. Flow chart of participant
recruitment is listed in the appendix (appendix, Figure 1, p27). Enrol-
ment of patients and controls occurred at a ratio of approximately 2:1.
All controls were screened for symptoms of respiratory viral illness or
history of contact with infected individuals prior to the study visit. Only
those individuals who were asymptomatic for COVID-19 were invited
and underwent a screening SARS-CoV-2 immunoglobulin test. Controls
were prospectively enrolled in parallel to recruitment of COVID-19
patients and group-matched for baseline characteristics including age,
gender, body mass index, risk factors such as smoking, hypertension,
diabetes, coronary artery disease and stroke. Informed consent was
obtained from all participants using an ethically approved consent form.
For further details on inclusion and exclusion criteria of patients
and controls, refer to appendix, p2. COVID-19 severity on admission
was defined as per the World Health Organisation (WHO) interim
clinical guidance (appendix for definition, p2). Patients with severe/
end-stage multi-system comorbidities and contraindications to mag-
netic resonance imaging were excluded.
This study was registered at ClinicalTrials.gov (NCT04510025) and
approved in the United Kingdom by the North West Preston Research
Ethics Committee (reference 20/NW/0235).2.2. Study procedures
All subjects consented to have comprehensive multiorgan mag-
netic resonance imaging (MRI) of the brain, lungs, heart, liver, kid-
neys, six-minute walk (6MWT) test, spirometry, cardiopulmonary
exercise test (CPET), series of questionnaires, and blood tests.2.3. Multiorgan MRI protocol
A 70 minute multiorgan MRI scan was carried out at 3 Tesla
(Prisma, Siemens Healthineers, Erlangen, Germany). Brain MRI
included T1weighted imaging, T2-Fluid attenuated inversion recovery
(FLAIR) to assess (e.g.) inflammation, diffusion-weighted imaging
(DWI) to assess ischaemic injury, susceptibility-weighted imaging
(SWI) to assess (e.g.) haemorrhage, and quantitative multi-inversion-
delay arterial spin labelling (ASL) to assess cerebral blood flow. Lung
imaging included a T2-weighted halfFourieracquisition single
shot turbo spinecho (HASTE) to qualitatively assess the extent of
lung parenchymal involvement. Cardiac assessment included cine
imaging, T1 and T2 mapping, post-contrast T1 mapping and late gado-
linium enhancement (LGE) imaging to assess biventricular volumes,
function, myocardial oedema, diffuse and focal/patchy fibrosis. Liver
imaging consisted of a single slice T1 map and multiecho gradient
echo IDEAL, to quantify fibro-inflammation (T1), fat (proton density
fat fraction, PDFF) and iron (T2*). Multiparametric renal imaging was
also undertaken and consisted of a single coronal oblique slice T1
Research in Context
Evidence before this study
We searched PubMed from the inception of our study to Sep-
tember 4th, 2020, for articles published in English, with the
search terms “COVID-19, multiorgan imaging, cardiac magnetic
resonance, brain magnetic resonance, abdominal magnetic reso-
nance, quality of life, cognitive assessment. cardiopulmonary
exercise test, follow-up”. There was no single study which has
comprehensively assessed multiple aspects of recovery in
patients with SARS-CoV-2 infections including multiorgan mag-
netic resonance imaging, quality of life, exercise tolerance, men-
tal health and cognition of patients after discharge from hospital.
There was one brain MRI study of COVID-19 survivors; however,
this did not formally assess cognition in patients. There were
three studies of cardiac magnetic resonance imaging in the early
and subacute phases of recovery in COVID-19. There were no
MRI studies of abdominal organs (kidneys or liver) in COVID-19
survivors and no study on cardiopulmonary exercise testing in
COVID-19 survivors at 2-3 months from disease onset. There
were three studies of pulmonary function testing and three stud-
ies that have assessed mental health in COVID-19 survivors.
There were no studies that systematically assessed cognition in
post-hospital discharged COVID-19 patients.
Added value of this study
This is the first holistic study of post-hospital discharged COVID-
19 patients to comprehensively assess the medium-term effects
of SARS-CoV-2 infection on multiple vital organs, exercise toler-
ance, mental, cognitive and physical health. We have shown that
a significant proportion of patients complained of symptoms of
breathlessness and fatigue at 2-3 months after the onset of ill-
ness and that MRI changes could be seen in the brain, lungs,
heart, liver and kidneys in a proportion of patients. An increased
burden of self-reported symptoms of depression and dysexecu-
tive cognitive profile were observed, as well as marked limita-
tions in exercise tolerance. Serum markers of inflammation and
severity of acute illness correlated with MRI evidence of multior-
gan abnormalities and reduced exercise tolerance.
Implications of all the available evidence
Our results, showing multi-system changes, highlight the need
to develop a multidisciplinary approach for the delivery of clini-
cal care to patients who are discharged following COVID-19 hos-
pital admissions. The high burden of self-reported mood
symptoms, abnormalities in executive cognitive performance,
perception of impaired quality of life and exercise tolerance limi-
tations carry implications for individuals who are expected to
return to work after hospital discharge. Further large-scale stud-
ies investigating the long-term effects of COVID-19 are war-
ranted, to fully understand the burden of chronic illness among
survivors of SARS-CoV-2 infections, and the long-term implica-
tions of multiorgan MRI abnormalities in patients.
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genation assessment (details in appendix, p2-5).
2.4. MRI Image analysis
All images were analysed quantitatively and qualitatively by
expert radiologist (XC), neuroradiologist (FS), cardiac MRI specialists
(BR, MC), neuroimage analysts (NF, LG, FA, TO, SS, KM, SM, FKM, CW,CA, FL, JA, MJ) and physicists (EMT, FEM) in a blinded fashion. Lung
MRIs were qualitatively assessed for parenchymal involvement by an
expert radiologist (XC). Extent of lung parenchymal abnormalities
was scored as 0 (0%), 1 (125%), 2 (2650%), 3 (5175%), or 4
(76100%), respectively. Brain image processing was carried out
using an adapted version of the processing pipeline created for the
United Kingdom (UK) Biobank brain imaging analysis (https://www.
fmrib.ox.ac.uk/ukbiobank/), based around tools from the Oxford Cen-
tre for Functional Magnetic Resonance Imaging of the Brain (FMRIB)
software library [FSL (https://fsl.fmrib.ox.ac.uk/fsl)] (appendix, p3).
Assessment of cardiac volumes, function, myocardial T1 maps, T2
maps, post-contrast T1 maps and LGE LGE images was undertaken
using cvi42 software (Circle Cardiovascular Imaging Inc., Version
5.10.1, Calgary, Canada) (appendix, p4). Quantitative analyses of T1
and T2* for liver, spleen and renal images were carried out as
described in the appendix (appendix, p5), including iron-correction
for liver T1 with an algorithm related to LiverMultiScan cT1 (Perspec-
tum, Oxford) but lacking cross-scanner standardisation and therefore
not comparable to LiverMultiScan cT1 .
2.5. Spirometry
Spirometry, including forced vital capacity (FVC), and forced expi-
ratory volume at the first second of exhalation (FEV1), was performed
as per recommended guidance (appendix, p5). [8]
2.6. CPET
Symptom-limited CPET was undertaken using a cycle ergometer.
Following two minutes of unloaded cycling, the work rate was
increased to 20W, followed by a 10W/min ramp. [9] Participants
were encouraged to reach their maximal work rate (appendix, p6).
2.7. Six-minute walk test
Participants were asked to walk for six-minutes in a pre-marked
corridor. Borg scale, heart rate and oxygen saturation were measured
immediately before and after the test (appendix, p5).
2.8. Questionnaires
Questionnaires were completed using an electronic data capture
(CASTOR EDC, https://www.castoredc.com). Depression, anxiety and
quality of life measures were assessed using the Patient Health Ques-
tionnaire (PHQ) depression module (PHQ-9) [10], General Anxiety
Disorder Questionnaire (GAD-7) [11] and Short Form-36 (SF-36) sur-
vey [12]. Cognitive function was assessed using the Montreal Cogni-
tive Asessment (MoCA) [13]. The Medical Research Council (MRC)
dyspnoea [14] scale, Dyspnoea-12 score [15] and Fatigue Severity
Scale (FSS) [16] were used to assess the extent of breathlessness and
fatigue, respectively (appendix for details, p6).
2.9. Laboratory assessments
Blood-based testing consisted of a complete blood count, bio-
chemical analysis, coagulation testing, assessment of liver and renal
function, markers of cardiac injury and measures of electrolytes, C-
reactive protein (CRP), procalcitonin, and lactate dehydrogenase.
2.10. Admission data collection and blood tests
Details on clinical symptoms or signs, vitals and laboratory find-
ings during admission were extracted from electronic medical
records. The severity of disease during hospital admission was graded
as per the WHO ordinal scale for clinical improvement (appendix for
definition, p2). [17]
Table 1




Age, years 55¢4 (13¢2) 53¢9 (12¢3) 0¢62
Sex 1¢00ᶞ
Female 24/58 (41¢4%) 12/30 (40¢0%)
Male 34/58 (58¢6%) 18/30 (60¢0%)
BMI, kg/m2 30¢8 (26¢2 - 36¢4) 27¢3 (23¢1 - 35¢1) 0¢17⁺
Black/Asian and minority ethnic groups 13/58 (22¢4%) 1/30 (3¢3 %) 0¢03
Current/Ex-smoker 20/58 (34¢5%) 7/30 (23¢3%) 0¢34ᵋ
Type 1 Diabetes 1/58 (1¢7%) 0/30 (0¢0%) 1¢00ᵋ
Type 2 Diabetes 8/58 (13¢8%) 3/30 (10¢0%) 0¢74ᵋ
Hypertension 22/58 (37¢9%) 9/30 (30¢0%) 0¢49ᵋ
Coronary artery disease 2/58 (3¢4%) 0/30 (0¢0%) 0¢55ᵋ
Cerebrovascular Disease 1/58 (1¢7%) 0/30 (0¢0%) 1¢00ᵋ
Asthma 20/58 (34¢5%) 6/30 (20¢0%) 0¢22ᵋ
COPD 3/58 (5¢2%) 0/30 (0¢0%) 0¢55ᵋ
Previous cancer 2/58 (3¢4%) 3/30 (10¢0%) 0¢33ᵋ
Depression 3/58 (5¢2%) 1/30 (3¢3%) 1¢00
Vital signs at follow-up
Heart rate, bpm 76¢3 (14¢1) 70¢2 (12¢1) 0¢047
Systolic pressure, mmHg 139¢7 (16¢5) 137¢2 (17¢0) 0¢51
Diastolic pressure, mmHg 79¢5 (71¢8 - 86¢8) 71¢5 (63¢0 - 87¢8) 0¢12⁺
Temperature, oC 36¢6 (36¢5 - 36¢7) 36¢5 (36.4 - 36¢6) 0¢047⁺
Oxygen saturation, % 96¢0 (95¢0 - 97¢0) 97¢0 (96¢0 - 98¢0) 0¢008⁺
Respiratory rate, respirations/minute 18¢0 (17¢8 - 20¢0) 16¢0 (13¢8 - 18¢0) <0¢001⁺
Admission details
Median length of stay, days 8¢5 (5¢0 - 17¢0)
Readmitted 10/58 (17¢2%)






















Chest pain 16/58 (27¢6%)
Headache 13/58 (22¢4%)
Vomiting 9/58 (15¢5%)
Fever on admission 39/58 (67¢2%)
<37¢5ᵒC 19/58 (32¢8%)
37¢5°C - 38¢0ᵒC 12/58 (20¢7%)
38¢1°C - 39ᵒC 19/58 (32¢8%)
>39°C 8/58 (13¢8%)
Treatment
Oxygen replacement 54/58 (93¢1%)
Nasal cannula 14/58 (24¢1%)
Simple face mask 7/58 (12¢1%)
Venturi face mask 6/58 (10¢3%)




Inotropic support 4/58 (6¢9%)





Acute liver injury* 18/58 (31¢0%)
(continued)
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Table 1 (Continued)
COVID-19 CONTROL p-value
Acute kidney injuryQ 6/58 (10¢3%)
Acute cardiac injury0 3/38 (7¢8%)
Pulmonary embolism 7/58 (12¢1%)
Central 1/58 (1¢7%)
Peripheral 6/58 (10¢3%)
Data are mean (SD), median (IQR) and n/N (%), where N is the total number of participants with
available data. p-values from independent Student’s t-test, Mann-Whitney U test (⁺), Chi square (ᶞ)
or Fisher’s exact test (ᵋ). COPD = chronic obstructive pulmonary disease. ITU = intensive treatment
unit. qSOFA52 = quick sequential organ failure assessment52. CPAP = Continuous positive airway
pressure. ECMO = extracorporeal membrane oxygenation. WHO = world health organisation. *
defined as blood levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above
3x the upper reference limit (>135 IU/L or >126 IU/L, respectively), alkaline phosphatase or
gamma-glutamyltransferase above 2x the upper reference limit (>260 IU/L or >80 IU/L, respec-
tively).Q defined as an increase in serum creatinine of at least 26 umol/L within 48 hours, or 1¢5 to
2-fold increase from baseline.
0 defined as an acute rise in hypersensitive troponin I above the 99th percentile upper reference
limit (>34 ng/L). Control subjects were matched for co-morbidities as closely as possible.
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Continuous variables were described using mean and standard
deviation (SD) for parametric data and median with interquartile
range (IQR) for non-parametric data in the tables. Normality was
assessed by visual inspection of histograms. Differences between two
groups were evaluated using Student’s t-tests or Mann-Whitney U-
tests as appropriate. Categorical variables were reported as frequency
and percentages. Associations between two groups were compared
using the Chi-square test or Fisher’s exact test as appropriate. Pear-
son’s or Spearman’s correlation coefficients were used to describe the
relationship between two variables where relevant. Analyses of brain
imaging derived phenotypes (IDPs) were undertaken after Gaussiani-
sation of all continuous variables which were then deconfounded i.e.,
adjusting for age, sex, BMI, diastolic and systolic blood pressure,
smoking and head size. Gaussianisation refers to the process of quan-
tile normalisation or monotonic remapping of values resulting in a
Gaussian distribution, to ameliorate both effects of outliers and
highly skewed distributions. [18] The conventional level of statistical
significance of 5% was used and not corrected for multiple compari-
sons. Statistical analyses were performed using SPSS Version 26.0
(IBM, Armonk, NY, USA).
2.12. Role of the funding source
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, writing of the article, or the
decision to submit for publication.
3. Results
Mean age of the patient group was 55§13 years and 34/58 (59%)
were men (Table 1). Thirteen (22%) belonged to Black, Asian and
Minority Ethnic groups. Twenty one patients (36%) had required
intensive care unit (ICU) admission; 20/21 required mechanical ven-
tilation (non-invasive ventilation or intubation). Four patients
required renal replacement therapy or inotropic support. Median
duration of hospitalisation was 8¢5 days (IQR 5¢0  17¢0). Patients
were assessed between 2-3 months from disease-onset at median
interval of 2¢3 months (IQR 2¢06  2¢53) and median 1¢6 months
from discharge (IQR 1¢4  1¢8). Baseline characteristics of patients
and group-matched controls are listed in Table 1. At follow-up,
patients had a mildly increased resting heart rate (p = 0¢047), respi-
ratory rate (p = 0¢0004) and reduced oxygen saturation (0¢008) rela-
tive to controls.
MRI data (Table 2) were available for up to 54/58 patients [brain
MRI (n = 54), lung MRI (n = 53) and cardiac and abdominal MRI (n =52)] and 28/30 controls (study flowchart and summary of missing
data in appendix Figure 1, p27, and appendix Table 7, p25).
3.1. Lung health and exercise tolerance
During hospital admission, 54/58 (93%) patients had abnormal
chest X-ray or computed tomography (CT). At ~23 months, persis-
tent parenchymal abnormalities on lung MRI were present in 32/53
(60%) patients (Table 2, appendix Figure 2, p28). Thirty-six (64%)
experienced symptoms of significant breathlessness (MRC dyspnoea
score  2) and 30/55 (55%) complained of fatigue (FSS  4). On aver-
age, COVID-19 survivors had a significantly lower FEV1 (p = 0¢0004),
FVC (p < 0¢0001) and higher FEV1/FVC ratio (p = 0¢027) at follow-up
(Table 3). Abnormalities were noted in FEV1 % predicted in 6/56 (11%)
and FVC % predicted in 7/56 (13%). Patients covered a shorter distance
on 6MWT than controls (405§118m vs 517§ 106m, p < 0.0001).
Four (7%) patients desaturated at the end of the test. During CPET,
patients achieved lower peak oxygen uptake (VO2, represented as %
of predicted VO2 max, p < 0¢0001)) (Fig. 1), oxygen uptake efficiency
slope (p = 0.001) and higher ventilatory equivalent for carbon diox-
ide (VE/VCO2 slope, p < 0.0001) (Table 3, Fig. 1) compared to con-
trols. VE/VCO2 slope, a marker of ventilatory efficiency, was worse in
those with MRI lung parenchymal abnormalities versus those with-
out (Median 35, IQR (3243) versus 32, IQR (2934), p = 0¢007).
CPET was stopped early in 15/51 (29%) patients due to fatigue and
myalgia and 5/51 (10%) of patients due to breathlessness. VE/VCO2
and six-minute walk distance correlated with markers of inflamma-
tion (white cell count, C-reactive protein (CRP) and pro-calcitonin) in
patients (Fig. 1, appendix Table 4, p21).3.2. Brain health and cognition
During hospital admission, one patient developed a right occipital
stroke; follow-up brain MRI revealed signs of a mature infarct. Blinded
qualitative assessment (by expert neuroradiologist - FS) of brain MRI
at 2-3 months did not reveal group differences in burden of small ves-
sel disease, white matter hyperintensities, haemorrhage or ischaemic
changes between patients and controls (appendix Table 3, p20). No
statistically significant differences were seen in quantitative measure-
ments of grey matter volumes (globally and regionally), white matter
volumes and cerebral perfusion (appendix Table 2, p12). Compared to
controls, patients had a higher T2* signal on susceptibility-weighted
imaging in the left and right thalamus (p = 0¢022) (Fig. 1, Appendix
Fig. 3) and increased mean diffusivity in the left posterior thalamic
radiation (p = 0¢042) and left and right averaged sagittal stratum
(0¢020) (Table 2). Patients tended to have higher periventricular white
Table 2
Relevant MRI parameters in patients and controls.
COVID-19 CONTROL p-value
Lung MRI
Lung parenchymal abnormalities, % 32/53 (60¢4%) 3 (10¢7%) <0¢0001ᵋ
0 21/53 (39¢6%) 25/28 (89¢3%) 0¢0003ᵋ
1-25% 3/53 (5¢7%) 0/28 (0¢0%)
26 - 50% 8/53 (15¢1%) 2/28(7¢1%)
51 - 75% 9/53 (17¢0%) 0/28 (0¢0%)
> 75% 12/53 (22¢6%) 1/28 (3¢6%)
Cardiac MRI
T1, T2, post contrast T1 mapping analysis
Native T1 (basal myocardium), ms 1179¢7 (34¢4) 1149¢3 (24¢0) 0¢0001
> 1197 ms (>2SD from control mean) 13/50 (26¢0%) 1/28 (3¢7%) 0¢015ᵋ
Native T1 (mid myocardium), ms 1173¢1 (33¢6) 1150¢2 (32¢4) 0¢004
> 1215 ms (>2SD from control mean) 4/51 (7¢8%) 0/28 (0¢0%) 0¢29ᵋ
Native T1 (apical myocardium), ms 1177¢4 (44¢7) 1168¢3 (53¢2) 0¢42
> 1275 ms (>2SD from control mean) 1/50 (2¢0%) 1/28 (3¢6%) 1¢00ᵋ
Extracellular volume (basal myocardium), % 30¢4 (28¢3 - 31¢3) 28¢3 (26¢8 - 31¢5) 0¢12
Extracellular volume (mid myocardium), % 30¢1 (27¢2 - 31¢4) 29¢4 (27¢1 - 30¢7) 0¢41⁺
Extracellular volume (apical myocardium), % 28¢7 (27¢0 - 31¢6) 29¢7 (27¢2 - 31¢5) 0¢51⁺
T2 (basal myocardium), ms 41¢7 (2¢2) 41¢6 (2¢2) 0¢80
T2 (mid myocardium), ms 41¢8 (2¢2) 41¢1 (2¢3) 0¢21
T2 (apical myocardium), ms 43¢5 (3¢0) 43¢7 (3¢5) 0¢81⁺
Late gadolinium enhancement analysis
% LGE enhancement, % of left ventricular mass 0¢8 (0¢5 - 1¢9) 0¢6 (0¢3 - 1¢0) 0¢023+
Myocarditis pattern 6/52 (11¢5%) 2/28 (7¢4%) 0¢47ᵋ
Myocardial infarction 1/52 (1¢9%) 0 (0¢0%)
LV/RV insertion point 7/52 (13¢5%) 1/28 (3¢7%)
Mixed 0 (0%) 0 (0%)
Other 0 (0%) 0 (0%)
Liver analysis
T1, ms 832¢4 (127¢4) 778¢1 (98¢2) 0¢059
T2*, ms 17¢7 (4¢4) 17¢2 (3¢49) 0¢60
Iron-corrected liver T1, ms{ 861¢0 (99¢2) 803¢9 (106¢6) 0¢019
> 1016ms (>2SD from control mean) 5/52 (9¢6%) 1/28 (3¢6%) 0¢66ᵋ
Average proton density fat fraction, % 4¢9 (3¢1 - 9¢5) 3¢7 (2¢1 - 6¢5) 0¢18⁺
Extracellular volume, % 27¢3 (23¢0 - 31¢2) 27¢3 (17¢6 - 33¢6) 0¢60+
Renal analysis
T1 map anaylsis
Average cortex, ms 1597¢5 (91¢2) 1523¢1 (65¢5) 0¢0003
> 1652 ms (>2SD from control mean)) 15/51 (29¢4%) 0/28 (0¢0%) 0¢001ᵋ
Average corticomedullary differentiation, ms 385¢4 (335¢8 - 456¢4) 470¢8 (431¢5 - 496¢3) 0¢0002⁺
Brain analysis&
T2-FLAIR volumes
White matter hyperintensities, mm3 2305¢0 (1402¢0 - 4021¢0) 1457¢0 (654¢2 - 2700¢5) 0¢085&
Periventricular white matter hyperintensities, mm3 1884¢0 (1172¢0-3303¢0) 1305¢0 (525¢0 - 2284¢8) 0¢066&
Deep white matter hyperintensities, mm3 330¢5 (141¢0 - 863¢0) 213¢0 (83¢5 - 416¢8) 0¢20&
Susceptibility-weighted imaging, T2*
Left thalamus, ms 44¢2 (42¢0 - 46¢1) 42¢8 (39¢9 - 45¢3) 0¢047&
Right thalamus, ms 43¢9 (41¢7 - 45¢8) 42¢4 (40¢2 - 45¢0) 0¢034&
Left and right thalamus, ms 43.9 (42.0 - 45.8) 42.6 (40.3 - 45.2) 0¢022&
Diffusion weighted imaging, Mean diffusivity
Right posterior thalamic radiation, x10⁻⁶mm2/s 842¢0 (804¢5 - 871¢2) 813¢0 (787¢0 - 832¢8) 0¢20&
Left posterior thalamic radiation, x10⁻⁶mm2/s 831¢0 (814¢5 - 851¢5) 811¢0 (792¢2 - 828¢8) 0¢042&
Right sagittal stratum, x10⁻⁶mm2/s 840¢0 (799¢5 - 863¢5) 813¢0 (789¢2 - 828¢5) 0¢022&
Left sagittal stratum, x10⁻⁶mm2/s 789¢0 (776¢5 - 814¢0) 787¢0 (767¢2 - 791¢5) 0¢078&
Left and right (averaged) sagittal stratum, x10⁻⁶mm2/s 810¢0 (791¢0 - 834¢0) 791¢5 (779¢5 - 808¢8) 0¢020&
Data are median (IQR) for non-parametric data and mean (SD) for parametric data, and n/N (%), where N is the total number of
participants with available data. p-values from independent Student’s t-test, Mann-Whitney U test (⁺), or Fisher's exact test (ᵋ).
Brain image derived phenotypes (IDPs) were Gaussianised and deconfounded for typical brain confounders. p-values for brain
measurements were derived from a Gaussianised deconfounded model (&) and relate to independent Student’s t-test comparison
of this data. Raw data are presented in the table for ease of interpretation. All other parameters are listed in the appendix Table 2.
An in-house algorithm was used to calculate iron-corrected T1, so these values cannot be compared to the LiverMultiScan cT1.
FLAIR = Fluid attenuated inversion recovery. LV = left ventricle. LGE = Late gadolinium enhancement. RV = right ventricle. Con-
trol subjects were matched for co-morbidities as closely as possible.
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pared to controls.
Cognitive performance in the executive/visuospatial domain was
impaired among patients compared to controls (MoCA visuospatial
score 4 in 40% patients versus 16% in controls, p = 0¢01). Among
patients, 28% (16/58) had a totalMoCA score that was abnormal accord-
ing to the established cut-off of <26 compared to 17% (5/30) of con-
trols. Median MoCA scores in patients (27, IQR 25-29), however, were
not statistically significantly different from controls (28, IQR 27-29,p = 0¢146) (Fig. 1). Periventricular white matter hyperintensities
(pWMH) and right thalamic T2* correlated with white cell count
(pWMH: r = 0¢47, p = 0¢002; right thalamic T2*: r = 0¢29 p = 0.05) in
patients (appendix Table 4, p21), but not with cognitive performance.
3.3. Cardiac health
During admission, 38/58 (66%) were screened for cardiac involve-
ment with troponin (high sensitivity Troponin I). Three (8%) were
Table 3
Spirometry and cardiopulmonary exercise test results from patients and controls.
Spirometry COVID-19 CONTROL p-value
FVC, % predicted 108¢3 (22¢8) 131¢4 (21¢8) <0¢0001
< 80% 7/56 (12¢5%) 0/28 0¢090ᵋ
FEV1, % predicted 101¢4 (19¢7) 118¢7 (22¢1) 0¢0004
< 80% 6/56 (10¢7%) 1/28 (3¢6%) 0¢42ᵋ
FEV1/FVC 0¢77 (0¢73 - 0¢80) 0¢75 (0¢70 - 0¢78) 0¢027⁺
FEF25, % predicted 97¢0 (27¢6) 110¢1 (30¢4) 0¢020
FEF50, % predicted 81¢0 (23¢2) 86¢9 (24¢5) 0¢13
FEF75, % predicted 54¢5 (42¢8 - 70¢0) 54¢0 (48¢5 - 69¢5) 0¢60⁺
Peak expiratory flow, % predicted 105¢7 (27¢7) 114¢5 (24¢7) 0¢16
Cardiopulmonary exercise test
VO2 peak, % of predicted VO2 max 80¢5 (23¢1) 112¢7 (27¢0) <0¢0001
< 80% 28/51 (54¢9%) 2/27(7¢4%) <0¢0001ᵋ
Anaerobic threshold (% of predicted VO2 max) 40¢7 (36¢2 - 47¢5) 46¢8 (43¢3 - 51¢3) 0¢0005⁺
VE/VCO2 Slope 33¢4 (29¢2 - 40¢3) 28¢2 (26¢7 - 30¢0) <0¢0001⁺
Oxygen Uptake Efficiency Slope 1¢9 (1¢6 - 2¢4) 2¢7 (2¢0 - 3¢2) 0¢001⁺
Data are median (IQR) for non-parametric data and mean (SD) for parametric data, and n/N (%), where N is
the total number of participants with available data. p-values from independent Student’s t-test, Mann-
Whitney U test (⁺), or Fisher's exact test (ᵋ). FVC = Forced vital capacity. FEV1 = Forced expiratory volume
in 1 second. FEF25, FEF50, FEF75 = Forced expiratory flow at 25%, 50% and 75% of forced expiration, respec-
tively.VO2 = oxygen consumption. VE/VCO2 = ventilatory equivalent for carbon dioxide. Control subjects
were matched for co-morbidities as closely as possible.
B. Raman et al. / EClinicalMedicine 31 (2021) 100683 7found to have an elevated troponin during admission (>34 ng/L). At
follow-up, troponin was normal in all patients (appendix Table 1,
p9). Left ventricular function was normal and comparable between
groups. Right ventricular ejection fraction in patients ranged from 43
to 79%, and on average was normal and not different from controls
(p = 0¢85, appendix Table 2, p12). Slice-averaged basal and mid-ven-Table 4





0  4 (Minimal) 35/57 (
5  9 (Mild) 14/57 (
10  14 (Moderate) 3/57 (5
15 (Severe) 5/57 (8
Moderate or worse anxiety
10 (Moderate or more) 8/57 (1
PHQ-9
Score 3¢0 (1¢0
0 - 4 (Minimal) 33/57 (
5 - 9 (Mild) 13/57 (
10 - 14 (Moderate) 7/57 (1
15 (Moderately severe or severe) 4/57 (7
Moderate or worse mood symptoms
10 (Moderate or more) 11/57 (
SF-36 Domains
Physical Functioning 65¢0 (4
Role Limitations Due to Physical Health 25¢0 (0
Role Limitations Due to Emotional Health 33¢3 (0
Energy 45¢0 (2
Emotional Well-Being 76¢0 (6
Social Functioning 50¢0 (3
Pain 67¢5 (3
General Health 68¢8 (4
Dyspnoea - 12 symptom score
Median (IQR) 4¢0 (1¢0
Fatigue Severity Scale
Median (IQR) 34 (18 -
/4 30/55 (
Medical Research Council Dyspnoea Scale
MRC grade 2 - 5 36/56 (
Data are median (IQR) and n/N (%), where N is the total n
from Mann-Whitney U test (+) or Fisher's exact test (ᵋ). G
PHQ-9 = Patient health questionnaire-9 assessment. SF-3
cil Scale. Control subjects were matched for co-morbidititricular native T1, a marker of fibrosis or inflammation on cardiac
MRI, were significantly elevated in patients (p = 0¢0001, p = 0¢004,
respectively) (Table 2, Fig. 1). Basal myocardial T1 was elevated (> 2
SD from average control T1) in 26% (13/50) of patients. Mid myocar-
dial T1 was elevated in 8% (4/51) and average of base and mid myo-
cardial T1 in 24% (12/50) of patients. Native T2, a marker of oedema,F-36) and symptom (dyspnoea, fatigue) burden in
19 CONTROL p-value





4%) 1/30 (3.3%) 0.16ᵋ





19¢3%) 1/30 (3¢3%) 0.051ᵋ
5¢0 - 90¢0) 92¢5 (83¢8 - 100¢0) <0¢0001⁺
¢0 - 75¢0) 100¢0 (100¢0 - 100¢0) <0¢0001⁺
¢0 - 100¢0) 100¢0 (100¢0 - 100¢0) <0¢0001⁺
5¢0 - 70¢0) 65¢0 (55¢0 - 80¢0) <0¢0001⁺
2¢0 - 88¢0) 84¢0 (72¢0 - 92¢0) 0¢044⁺
7¢5 - 87¢5) 100¢0 (62¢5 - 100¢0) 0¢0002⁺
5¢0 - 90¢0) 85¢0 (67¢5 - 100¢0) 0¢003⁺
3¢8 - 81¢3) 75¢0 (60¢9 - 87¢5) 0¢022⁺
- 11¢0) 0¢0 (0 -1¢5) <0¢0001+
49) 17 (11 - 24) 0¢001+
54¢5%) 5/29 (17¢2%) 0¢010ᵋ
64¢3%) 3/29 (10¢3%) <0¢0001ᵋ
umber of participants with available data. p-values
AD-7 = Generalised anxiety disorder-7 assessment.
6 = Short form 36. MRC = Medical Research Coun-
es as closely as possible.
Fig. 1. Systemic effects of COVID-19 and relationship with inflammatory response. A, B: Comparison of cardiopulmonary exercise test (CPET) parameters (VO2 max and VE/VCO2)
between comorbidity-matched control and COVID-19 survivors. C: Relationship between VE/VCO2 and white cell count in COVID-19. D, E: Comparison of susceptibility weighted
T2* signal (left and right thalamus) and MoCA scores between control and COVID-19 survivors. F: Relationship between periventricular white matter hyperintensity volume
(pWMH) volume and white cell count in COVID-19. G, H: Comparison of myocardial native T1 (base and mid ventricle) between control and COVID-19 survivors. I: Relationship
between basal native T1 and C-reactive protein (CRP). J, K: Comparison of liver T1 and iron-corrected liver T1 between control and COVID-19 survivors (these values cannot be
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Fig. 2. A: Quality of life (Short Form-36) radar plot for patients and controls. B,C: Burden of depression and anxiety among patients. A: The radar plot demonstrates that patients
with COVID-19 (blue line) were more likely to experience impairment in energy, general health, physical health, social and emotional well-being and increased pain when com-
pared to controls (orange line). Both physical and emotional factors caused significant role limitations among patients. B, C: 19% of hospitalised COVID-19 patients had moderate to
severe self-reported symptoms of depression and 14% of hospitalised COVID-19 patients had moderate to severe self-reported symptoms of anxiety.
B. Raman et al. / EClinicalMedicine 31 (2021) 100683 9was not different between patients and controls (p = 0¢80, 0¢21
and 0¢81 for basal, mid and apical values, respectively). Extracellu-
lar volume fraction (a measure of diffuse fibrosis) tended to be
higher in the base but the numerical differences failed to reach sta-
tistical significance (Table 2). Focal fibrosis burden was mildly
increased in patients. Both basal and mid-ventricular myocardial
T1 correlated moderately (appendix, p2 for definition) with CRPcompared to the LiverMultiScan cT1). L: Relationship between iron-corrected liver T1 and CRP
ferentiation in control and COVID-19 survivors. O: Relationship between average cortical kid
variables; Spearman’s correlation coefficient and p-values are reported for correlations, # sig
deconfounded).and pro-calcitonin in patients (appendix Table 4, p21, Fig. 1), but
not in controls (p > 0¢1).
3.4. Liver health
Acute liver injury (appendix, p2) was seen in 31% (18/58) of patients.
At 2-3 months, 11% had persistent liver injury (non-specific pattern) onin COVID-19. M, N: Comparison of average cortical kidney T1 and corticomedullary dif-
ney T1 and CRP in COVID-19 (p-values for comparisons are from Student’s t-tests for all
nifies p-values were derived from comparison of variables that were Gaussianised and
10 B. Raman et al. / EClinicalMedicine 31 (2021) 100683blood tests (appendix Table 1, p9). On MRI, another 10% (5/52) of
patients had signs of liver injury evidenced by increased iron-corrected
liver T1 (Table 2, Fig. 1). Iron-corrected liver T1 is a histologically vali-
dated imaging biomarker of hepatic fibro-inflammation, [19] which has
subsequently been developed in LiverMultiScan where it is increasingly
being used to monitor the response of hepatitis to novel therapies. [20]
By contrast, no statistically significant differences were seen in liver fat
(p=0¢18), iron (p=0¢60) and extracellular volume fraction (a marker of
diffuse fibrosis, p=0¢60) between both groups. Iron-corrected liver T1
correlated moderately with systemic markers of inflammation (white
cell count, neutrophil, monocyte count and CRP) in patients (appendix
Table 4, p21), but also in controls.
3.5. Haematological system and spleen
Haematological abnormalities including lymphocytopenia and
thrombocytopenia were seen in 47% (27/58) and 2% (1/58) of patients
at admission respectively and an elevated CRP during admission
(>10mg/L) was seen in 98% (57/58). At follow-up, all abnormalities in
lymphocyte and platelet count returned to normal. However, the
higher CRP in patients versus controls approached statistical signifi-
cance (p = 0¢058) (appendix, Table 1, p9). There were no statistically
significant differences in splenic volume and tissue characteristics on
MRI between patients and controls (p = 0.47, 0.37 and 0.93 for spenic
volume, T1 and T2*, respectively) (appendix Table 2, p12).
3.6. Kidney health
Six (10%) patients developed acute kidney injury (Table 1 for
breakdown and definition, appendix p2), of whom two required renal
replacement therapy during admission. At 2-3 months, 3% (2/58) of
patients had residual renal impairment which was not present prior
to COVID-19. On average, creatinine and estimated glomerular filtra-
tion rate were not significantly different between patients and con-
trols (p = 0¢16 and 0¢70, respectively, appendix Table 1, p9). Despite
this, both average (left and right) renal cortical T1 and corticomedul-
lary differentiation, markers of renal injury/fibro-inflammation, were
abnormal in patients (Table 2, Fig. 1). A significantly higher renal cor-
tical T1 (>2 SD than control mean) was seen in 29% (15/51) of
patients. Patients with acute kidney injury during admission had a
higher average renal cortical T1 (1711§90ms versus 1582§81ms,
p = 0¢001) and lower corticomedullary differentiation (318§59 versus
405§83, p =0¢016; appendix Figure 2, p28) compared to those with-
out. Kidney oxygenation did not differ between patients and controls
(p = 0¢51, appendix Table 2, p12). Average renal cortical T1 had a mod-
erate correlation with markers of inflammation (CRP, pro-calcitonin)
in patients at follow-up (appendix Table 4, p21).
3.7. Mental health and quality of life
At 2-3 months, patients had higher cumulative self-reported
symptom scores for depression (PHQ-9 median score 3 versus 1¢5,
p = 0¢009) compared to controls (Table 4). Symptom score for anxi-
ety also tended to be higher (GAD-7 median score 2¢0 vs 0¢5,
p = 0¢066) in patients compared to controls. 19% of patients reported
symptoms of moderate to severe depression and 14% of patients had
symptoms of moderate to severe anxiety (Fig. 2). Patients also
reported a significantly reduced quality of life in all domains (Table 4,
Fig. 2). Importantly, impairment in both physical and emotional
health imposed significant role limitations among COVID-19 survi-
vors. The severity of depression and anxiety did not consistently
associate with markers of inflammation (except for monocyte count)
or multiorgan injury among patients (appendix Table 4, p21). How-
ever, a moderate correlation was seen between extent of mood
symptoms (PHQ-9 score) and anxiety (GAD-7 score) and ongoing
breathlessness (MRC dyspnoea score) (PHQ-9 and MRC dyspnoeascore: r = 0¢58, p< 0¢0001, GAD-7 and MRC dyspnoea score: r = 0¢41,
p = 0¢002).
3.8. Severity of disease and persistent inflammation
Severity of illness during admission (WHO ordinal scale) (appen-
dix Table 4, p21, Table 5, p23) correlated moderately with inflamma-
tory markers (Procalcitonin, CRP, white cell count, neutrophil count
monocyte count) at follow-up, signs of persistent inflammation/
injury in the lungs, liver, kidneys, and exercise tolerance. Notably,
even in patients who were not critically ill (i.e, those who were not
intubated or ventilated or receiving vasopressor/ionotropic support
or renal replacement therapy), MRI evidence of lung, cardiac, kidney
and brain abnormalities could be seen (appendix Table 6, p24). Hos-
pitalised-patients with more severe disease were more likely to also
experience persistent breathlessness (r = 0¢268, p = 0¢046), but
severity of illness did not predict risk of depression or anxiety.
4. Discussion
The present holistic study uniquely characterised the medium-
term effects of COVID-19 infection on multiple vital organs, func-
tional capacity, mental health and cognition in post-hospital survi-
vors of moderate to severe infection. The key findings of our study
are: First, at 2-3 months from disease-onset, a proportion of patients
displayed abnormalities in the lungs, brain, heart, liver and kidneys
on MRI. Second, the severity of acute illness during admission corre-
lated with some markers of multiorgan injury at follow-up. Third,
limitations in exercise tolerance (CPET and six-minute walk distance)
and imaging biomarkers associated with blood inflammatory
markers. Deconditioning as assessed by CPET, symptoms of persistent
breathlessness, and fatigue were prominent among patients and
interfered with activities of daily living and quality of life. Finally,
patients had a higher burden of self-reported mood symptoms which
related to symptoms of persistent breathlessness at follow-up.
Studies examining the temporal evolution of lung abnormalities
on serial high-resolution CT scans have revealed that persistent
inflammatory changes may be seen in up to 71% of COVID-19 survi-
vors at two to three months post discharge. [7,21] Consistent with
this, we observed a high proportion of parenchymal abnormalities on
lung MRI, albeit at a lower frequency than that seen on CT. Previous
investigations have shown that survivors of SARS pneumonia can be
left with more permanent lung damage [22] and abnormalities in
lung function for months to even years after infection. In our study,
13% of patients exhibited abnormalities on spirometry (FVC) at 23
months. Although we were unable to assess diffusion capacity (DLCO)
in our patients, our findings are in line with a recent report by Mo
and colleagues, who demonstrated similar anomalies on spirometry
and additionally described an impairment in DLCO in up to 47% of
cases. [23]
Occult neurological injury has been suspected in COVID-19 due to
a high burden of non-specific neurological symptoms. [24] Although
neurological symptoms were frequent (~50%) in our unselected
cohort, imaging evidence of severe neurologic injury on MRI was
rare. Nevertheless, patients demonstrated increased bilateral tha-
lamic T2* signal on susceptibility-weighted imaging and increased
mean diffusivity in posterior thalamic radiations and sagittal stratum.
Susceptibility-weighted imaging is often used to detect blood break-
down products and calcification. [25] That these abnormalities could
reflect a higher burden of microvascular events among COVID-19 sur-
vivors is tentatively supported by a slightly increased volume of
white matter hyperintensities among patients. This would be consis-
tent with the higher frequency of cerebrovascular events reported by
others. [24] While the exact pathophysiology underlying the cerebro-
vascular disease is yet to be clarified, it is possible that a combination
of hypercoagulable state acutely and chronic neuroinflammatory
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sity volumes, [26] T2* abnormalities and inflammatory markers, play
an important role. The cognitive profile observed (primarily dysexec-
utive) among patients is also consistent with a vascular pattern, repli-
cating previous reports of dysexecutive syndrome in COVID-19
survivors [27]. Although this cross-sectional data limit the extent to
which causal associations can be made, our findings suggest a poten-
tial link between COVID-19 and future risk of cognitive decline, [28]
given that both white matter hyperintensities [2931] and vascular
injury [32] on brain MRI are emerging as potent predictors of demen-
tia risk in individuals.
Evidence of acute myocardial injury can be seen in up to a third of
hospitalised patients with moderate to severe SARS-CoV-2 infection
and associates with fatal outcomes. [2,33] Cardiac MRI can to be particu-
larly useful in providing a diagnosis in patients with suspected cardiac
involvement. [34] In a recent study by Puntmann and colleagues, [35]
cardiac MRI showed evidence of a high burden of inflammation (60% of
patients), as seen by elevated native T1, T2 and some biventricular
impairment in convalescing patients, a third of whom required hospital-
isation. In our study of previously hospitalised patients, only 26% had a
significantly elevated native T1. Native T2 and cardiac function did not
differ from our risk-factor matched cohort, consistent with an earlier
study [34]. A point worth noting is that differences in prevalence esti-
mates on MRI studies may arise from variations in ‘reference ranges’,
methodological differences, and patient characteristics. Our approach to
use a risk-factor matched control group (prospectively enrolled under
identical scan conditions) as reference suggests that abnormal MRI tis-
sue characteristics in 26% of patients could not be explained by the
comorbidities alone. Furthermore, myocardial native T1 moderately cor-
related with serum markers of inflammatory response (CRP, white cell
count, neutrophil count and procalcitonin), indicating myocardial tissue
abnormalities were linked to inflammation.
Several independent investigations [3,4] have confirmed a high
prevalence of acute liver injury in hospitalised patients. Potential
mechanisms include hyperinflammatory syndrome, hypoxia-mediated
metabolic derangements, venous thrombosis and drug-induced hepa-
titis. [36] Direct infection of cholangiocytes has also been suggested, as
SARS-CoV-2 may injure the bile ducts by binding to ACE2 receptors.
[37] We observed that 11% of patients had persistent blood biomarker
evidence of liver injury at 23 months, and another 10% demonstrated
increased iron-corrected liver T1, a marker of liver fibro-inflammation
[19]. Iron-corrected liver T1 also correlated with serum biomarkers of
inflammation, providing further evidence that multiorgan health is
worse in those with a higher burden of inflammation.
The kidneys are amongst the most common targets of SARS-CoV2,
with acute kidney injury reported in 0.537% of hospitalised
patients. [24,38,39] Direct infection of renal cells may occur via
ACE2 receptors which are enriched in podocytes and endothelial
cells. [40] Associated histopathological abnormalities include promi-
nent lymphocytic endothelitis, acute tubular necrosis, diffuse eryth-
rocyte aggregation, peritubular obstruction and podocyte injury. [40]
We showed that 29% of patients had abnormal renal tissue character-
istics on MRI. In particular, renal cortical T1, a marker of renal inflam-
mation/injury was prolonged and accompanied by a loss of
corticomedullary differentiation, reminiscent of other post-inflam-
matory glomerulonephritides. [41] Patients with more severe disease
(i.e, acute kidney injury, need for higher oxygen support) and higher
inflammatory burden were more likely to have abnormal cortical T1
and corticomedullary differentiation at follow-up.
Chronic inflammation represents a sustained reaction of the
immune system to an inflammatory stimulus (i.e, viral nucleic acid)
accompanied by tissue damage. [42] The association of multiple
imaging markers of organ abnormalities and inflammatory response
in patients, but not in controls, raises the possibility that persistent
inflammation could play a role in mediating multiorgan abnormali-
ties. [43] Another explanation is that COVID-19 recovery is slow,resulting in persistence of tissue abnormalities and increased CRP
even at 3 months from disease onset. Although critical illness has
also been shown in prior studies to associate with systemic inflam-
mation [44], we found that MRI evidence of multiorgan abnormalities
was not limited to patients with critical disease alone. Further efforts
to understand the mechanisms underlying multiorgan damage, and
strategies to arrest them could limit the long-term detrimental
effects of COVID-19 on vital organs.
Insights from earlier studies of SARS survivors [45] have raised
concerns that limitations in exercise tolerance may persist for
months after infection. In our study, patients achieved a shorter six-
minute walk distance, lower peak VO2 and lower % of predicted VO2
max at the anaerobic threshold (VT1). VE/VCO2 slope, a measure of
ventilatory efficiency, was worse in patients with parenchymal
abnormalities and both VE/VCO2 and six-minute walk distance corre-
lated with markers of systemic inflammation. Of note, many patients
stopped CPET early because of generalised muscle ache and fatigue
rather than breathlessness. These findings suggest that muscle wast-
ing, secondary to a catabolic state induced by severe illness [46] and
potentially inflammation [47], may also contribute to exercise limita-
tions in the patients with moderate to severe infection.
In addition to coping with the debilitating acute effects of COVID-19,
survivors experience a range of mental stressors whilst in-hospital and
after discharge. We and others [48,49] have observed a high-level of
self-reported symptoms of depression among survivors. Infection-trig-
gered cytokine dysregulation and the neurotropic potential of SARS-
CoV-2 have widely been speculated to induce psychopathological
sequelae among patients, consistent with neuroinflammatory mecha-
nisms implicated in other psychiatric disorders. [50] Here, although the
burden of ongoing symptoms of breathlessness associated with mood
and anxiety symptoms, we did not see a consistent association between
disease severity and depression. Given the limited sample size of our
study, a more focussed approach in a larger cohort could yield further
insights into such relationships and offers the potential to identify novel
targets for neuropsychiatric therapeutic modulation.
The relatively small sample size of this single-centre study, cross-
sectional nature of some assessments and lack of correction for multi-
ple comparisons are important limitations which curtail the general-
isability of our findings and accuracy of prevalence estimates. The
lack of pre-COVID-19 imaging limits our ability to make causal infer-
ences about the mechanism of MRI tissue abnormalities. However,
this is the first exploratory study to comprehensively assess multiple
vital organs, mental, cognitive and physical health in patients with
COVID-19 post-hospital discharge. These findings underscore the
need for further large scale investigations as is currently planned by
Public Health England through the Post-HOSPitalisation COVID-19
(PHOSP-COVID) [51] national consortium and its two MRI sub-studies
C-MORE and COVERSCAN. The use of lung MRI could have underesti-
mated the prevalence of lung injury. Controls in our study were not
hospitalised, thus group differences may not be COVID-19 specific.
There were ethnoracial differences between the control and patients
enrolled in this study which may have contributed to prevalence esti-
mates of multiorgan injury. Finally, whether the findings on MRI have
any long term clinical implications remains to be determined by fur-
ther longitudinal follow-up studies.
Our findings underscore the need to further understand the path-
ophysiological mechanisms underpinning multiorgan MRI tissue
abnormalities and to provide a holistic-integrated multidisciplinary
model of clinical care for patients recovering from COVID-19 post
hospital discharge.
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